Insider Selling: Replimune Group (NASDAQ:REPL) CFO Sells 14,709 Shares of Stock

Replimune Group, Inc. (NASDAQ:REPL – Get Free Report) CFO Emily Hill sold 14,709 shares of the company’s stock in a transaction that occurred on Monday, November 16th. The shares were sold at an average price of $21.60, for a total value of $317,714.40. Following the completion of the transaction, the chief financial officer owned 201,143 shares in the company, valued at approximately $4,344,688.80. The trade was a 6.81% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Replimune Group Stock Performance

NASDAQ REPL traded up $0.12 on Wednesday, hitting $19.81. 2,130,078 shares of the stock traded hands, compared to its average volume of 3,489,130. The business’s fifty day moving average is $15.10 and its two-hundred day moving average is $10.23. Replimune Group, Inc. has a 12 month low of $1.50 and a 12 month high of $23.54. The firm has a market capitalization of $1.88 billion, a price-to-earnings ratio of -7.10 and a beta of 0.93. The company has a debt-to-equity ratio of 0.59, a quick ratio of 6.90 and a current ratio of 7.11.

Replimune Group (NASDAQ:REPL – Get Free Report) last released its earnings results on Wednesday, October 28th. The company reported ($0.54) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.78) by $0.24. As a group, equities analysts anticipate that Replimune Group, Inc. will post -2.38 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

Several equities research analysts recently weighed in on REPL shares. Weiss Ratings reissued a “sell (e+)” rating on shares of Replimune Group in a report on Wednesday, November 4th. Wall Street Zen raised shares of Replimune Group from a “sell” rating to a “hold” rating in a report on Saturday, October 31st. Wedbush raised shares of Replimune Group from a “neutral” rating to an “outperform” rating and set a $12.00 price objective on the stock in a report on Friday, August 7th. Cantor Fitzgerald reiterated an “overweight” rating on shares of Replimune Group in a research report on Monday, October 5th. Finally, JPMorgan Chase & Co. lifted their target price on shares of Replimune Group from $20.00 to $21.00 and gave the stock an “overweight” rating in a research note on Wednesday, August 26th. Seven investment analysts have rated the stock with a Buy rating, one has assigned a Hold rating and two have assigned a Sell rating to the company. According to data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average price target of $18.17.

View Our Latest Stock Report on REPL

Institutional Investors Weigh In On Replimune Group

Institutional investors have recently made changes to their positions in the stock. BlackRock Inc. bought a new position in shares of Replimune Group in the second quarter worth $99,171,000. Marshall Wace LLP bought a new stake in shares of Replimune Group during the 3rd quarter valued at $50,516,000. Montanova Capital LLC raised its stake in shares of Replimune Group by 4.0% during the 2nd quarter. Montanova Capital LLC now owns 4,389,836 shares of the company’s stock valued at $48,595,000 after purchasing an additional 168,000 shares during the period. Opaleye Management Inc. bought a new stake in shares of Replimune Group during the 2nd quarter valued at $15,332,000. Finally, Dimensional Fund Advisors LP lifted its holdings in Replimune Group by 1.9% during the 1st quarter. Dimensional Fund Advisors LP now owns 1,140,099 shares of the company’s stock worth $8,719,000 after purchasing an additional 20,742 shares in the last quarter. Hedge funds and other institutional investors own 92.53% of the company’s stock.

Replimune Group Company Profile

(Get Free Report)

Replimune Group is a biotechnology company focused on developing tumor-directed immunotherapies for people with cancer. Its proprietary platform uses genetically modified herpes simplex viruses, designed to be injected into tumors and stimulate an immune response against cancer. The company’s investigational pipeline includes RP1, an engineered oncolytic virus that expresses proteins intended to promote tumor cell destruction and immune activation. Replimune is also developing other candidates that combine virus-based treatment with additional immune-stimulating approaches.

Further Reading

Insider Buying and Selling by Quarter for Replimune Group (NASDAQ:REPL)

Receive News & Ratings for Replimune Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Replimune Group and related companies with MarketBeat.com's FREE daily email newsletter.